TBIO — Telesis Bio Share Price
0.000.00%
Last trade - 00:00- $1.64m
- $3.54m
- $27.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.42 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -235.95% | ||
| Return on Equity | -181.54% | ||
| Operating Margin | -347.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.8 | 6.58 | 11.04 | 27.43 | 27.51 | 9.2 | 9.6 | 54.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- March 24th, 2011
- Public Since
- June 18th, 2021
- No. of Shareholders
- 37
- No. of Employees
- 137
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,775,839
- Address
- 10431 Wateridge Circle, Suite 150, SAN DIEGO, 92121
- Web
- https://telesisbio.com/
- Phone
- +1 8582284115
- Auditors
- WithumSmith Brown PC
Upcoming Events for TBIO
Telesis Bio Inc Annual Shareholders Meeting
Q1 2025 Telesis Bio Inc Earnings Release
Q2 2025 Telesis Bio Inc Earnings Release
Similar to TBIO
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Telesis Bio share price?
As of Today at 23:37 UTC, shares in Telesis Bio are trading at $0.92. This share price information is delayed by 15 minutes.
How has the Telesis Bio share price performed this year?
Shares in Telesis Bio last closed at $0.92 and the price had moved by -86.53% over the past 365 days. In terms of relative price strength the Telesis Bio share price has underperformed the S&P500 Index by -87.27% over the past year.
What are the analyst and broker recommendations for Telesis Bio?
The overall consensus recommendation for Telesis Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Telesis Bio dividend yield?
Telesis Bio does not currently pay a dividend.
Does Telesis Bio pay a dividend?
Telesis Bio does not currently pay a dividend.
When does Telesis Bio next pay dividends?
Telesis Bio does not currently pay a dividend.
How do I buy Telesis Bio shares?
To buy shares in Telesis Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Telesis Bio?
As of the previous close price of $0.92, shares in Telesis Bio had a market capitalisation of $1.64m.
Where are Telesis Bio shares listed?
Here are the trading details for Telesis Bio:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TBIO
What kind of share is Telesis Bio?
Based on an overall assessment of its quality, value and momentum Telesis Bio is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Telesis Bio share price forecast for 2025?
The analyst consensus target price for shares in Telesis Bio is $4.00. That is 334.02% above the last closing price of $0.92.
Analysts covering Telesis Bio currently have a consensus Earnings Per Share (EPS) forecast of -$24.95 for the next financial year.
Find out moreWhat is the trend in the Telesis Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Telesis Bio. Over the past six months, its share price has underperformed the S&P500 Index by -61.56%.
As of the last closing price of $0.92, shares in Telesis Bio were trading -50.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Telesis Bio PE Ratio?
The Telesis Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Telesis Bio?
We do not have data on Telesis Bio's directors